98%
921
2 minutes
20
A recent genome-wide association study indicated that rs11098403, a single nucleotide polymorphism in the vicinity of NDST3, was strongly associated with the risk of schizophrenia in Caucasians. However, this relation has not been validated in other populations or ethnic groups. Herein, we conducted a case-control study to investigate the association of rs11098403 polymorphism with the schizophrenia risk in a Han Chinese population comprising 440 schizophrenia patients and 450 control subjects. For the first time, we showed that the minor allele (G) of rs11098403 is closely associated with a reduced risk of schizophrenia (OR=0.614; 95% CI: 0.453-0.833; P=0.002; Power=0.832). Meanwhile, the G allele of rs11098403 seemed to reduce the schizophrenia risk via a dominant manner (GG+AG vs. AA, OR=0.526; 95% CI: 0.374-0.74; P<0.001). Furthermore, this association was further confirmed using an independent replication sample containing 267 schizophrenia patients and 400 control subjects with a Han Chinese descent (OR=0.652; 95% CI: 0.469-0.907; P=0.011; Power=0.772). Taken together, these findings demonstrate a significant association between rs11098403 and schizophrenia risk in Han Chinese, confirming the data that previously obtained from Caucasians.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neulet.2014.08.018 | DOI Listing |
Brain Behav
September 2025
Faculty of Medicine, Department of Internal Medicine, Psychiatry Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
Introduction: The readmission of individuals with schizophrenia to inpatient care poses a significant challenge for health practitioners, as this tendency has a culminating effect on the patients and their families. The duration of hospitalization of a patient with schizophrenia in a hospital or mental health facility poses a significant burden on mental healthcare systems. This study aimed to assess the length of stay of patients with schizophrenia in a mental health facility.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
August 2025
Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA.
Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
August 2025
Geriatric Medicine Department II, Qingdao Mental Health Center, Qingdao, Shandong, People's Republic of China.
Purpose: Previous studies have shown that serum uric acid (UA) levels are significantly higher in patients with bipolar disorder (BD) than in patients with depressive disorder (DD), schizophrenia, and healthy controls. Currently, studies generally report that there is a complex bidirectional interaction between mood disorders (MD) and hyperuricemia (HUA). We investigated the prevalence and related factors of hyperuricemia in Chinese patients with mood disorders to find out potential mechanisms and build a predictive model.
View Article and Find Full Text PDFIntegr Med Res
March 2026
KM Science Research Division, Korea Institute of Oriental Medicine, South Korea.
Background: Depression is a common comorbidity of schizophrenia spectrum disorder (SSDs) that affects functional outcomes and quality of life. This systematic review and meta-analysis evaluated the effectiveness of herbal medicine as an adjunct therapy to antipsychotics in patients with SSDs and comorbid depression.
Methods: Eight databases were searched from inception to January 2025 for randomized controlled trials (RCTs) evaluating herbal medicine combined with antipsychotics vs antipsychotics alone in patients with SSDs and comorbid depression.